Were Hedge Funds Right About Harpoon Therapeutics, Inc (HARP)? insidermonkey.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from insidermonkey.com Daily Mail and Mail on Sunday newspapers.
Hedge Funds Cashed Out Of AnaptysBio, Inc. (ANAB) Too Early
The Insider Monkey team has completed processing the quarterly 13F filings for the March quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors experienced strong gains on the back of a strong market performance, which certainly propelled them to adjust their equity holdings so as to maintain the desired risk profile. As a result, the relevancy of these public filings and their content is indisputable, as they may reveal numerous high-potential stocks. The following article will discuss the smart money sentiment towards AnaptysBio, Inc. (NASDAQ:ANAB).
Is Dicerna Pharmaceuticals (DRNA) a Smart Long-term Buy?
Baron Health Care Fund recently published its third-quarter commentary – a copy of which can be downloaded here. During the third quarter of 2020, the Baron Health Care Fund returned 11.64% (institutional shares). In comparison, the benchmark S&P 500 Index was up 8.93%, while the Russell 3000 Health Care Index was up 6.48%. You should check out Baron’s top 5 stock picks for investors to buy right now, which could be the biggest winners of 2021.
In the Q3 2020 Investor Letter, Baron Health Care Fund highlighted a few stocks and Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) is one of them. Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) is a biotechnology company. Year-to-date, Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) stock gained 9.0% and on December 10th it had a closing price of $24.02. Here is what Baron Health Care Fund said: